Fertility drugs and risk of ovarian cancer

LAUR Repository

Show simple item record

dc.contributor.author Zreik, Tony
dc.contributor.author Ayoub, Chakib
dc.contributor.author Hannoun, Antoine
dc.contributor.author Karam, Cynthia
dc.contributor.author Munkarah, Adnan
dc.date.accessioned 2015-10-07T05:58:31Z
dc.date.available 2015-10-07T05:58:31Z
dc.date.copyright 2008
dc.date.issued 2015-10-07
dc.identifier.issn 1040-872X en_US
dc.identifier.uri http://hdl.handle.net/10725/2265
dc.description.abstract Purpose of review: Worldwide 50–80 million people suffer from infertility. Assisted reproductive technology has provided a way of overcoming infertility and childlessness. The current article will focus on data linking infertility and its treatment to ovarian cancer. Recent findings: Ovarian cancer risks associated with fertility drug treatment are encouraging, but not decisive. In view of the limited ability to evaluate drug effects on borderline tumors, given their rare occurrence, studies involving patient reports of prior drug exposures have noted an elevated risk of borderline tumors associated with fertility drugs. Nevertheless, the risk of invasive ovarian cancer appears to be restricted to those women who remain childless despite the infertility treatment. Summary: As long as doubt persists, it might be advisable to reflect on a few clinical recommendations: identify high-risk infertile patients for ovarian cancer, investigate preexisting cancer before fertility treatment, inform patients regarding potential risks, obtain an informed consent, avoid exposure to long periods of ovulation induction cycles that are given before patients are referred for in-vitro fertilization and embryo transfer for women at greater risk and monitor women who have been treated with these drugs, especially those who failed to conceive, regularly and thoroughly. en_US
dc.language.iso en en_US
dc.title Fertility drugs and risk of ovarian cancer en_US
dc.type Article en_US
dc.description.version Published en_US
dc.title.subtitle Dispelling the myth en_US
dc.author.school SOM en_US
dc.author.idnumber 200802707
dc.author.woa N/A en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Current Opinion in Obstetrics and Gynecology en_US
dc.journal.volume 20 en_US
dc.journal.issue 3 en_US
dc.article.pages 313-319 en_US
dc.keywords Assisted reproductive technologies en_US
dc.keywords Clomiphene citrate en_US
dc.keywords Fertility treatment en_US
dc.keywords Gonadotropins en_US
dc.keywords Infertility en_US
dc.keywords Ovarian cancer en_US
dc.identifier.doi http://dx.doi.org/10.1097/GCO.0b013e3282fdc6c3 en_US
dc.identifier.ctation Zreik, T. G., Ayoub, C. M., Hannoun, A., Karam, C. J., & Munkarah, A. R. (2008). Fertility drugs and risk of ovarian cancer: dispelling the myth. Current Opinion in Obstetrics and Gynecology, 20(3), 313-319. en_US
dc.author.email tgzreik@lau.edu.lb
dc.identifier.url http://journals.lww.com/co-obgyn/Abstract/2008/06000/Fertility_drugs_and_risk_of_ovarian_cancer_.19.aspx

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account